Short answer
Stoke Therapeutics, Inc. (STOK) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $11M (up 117.3% year over year) with net income of −$38M.
Q3 2025 key financials · XBRL
- Revenue
- $11M
- +117.3% YoY · −23.1% QoQ
- Net income
- −$38M
- −45.1% YoY · −63.3% QoQ
- Operating margin
- -405.3%
- EPS (diluted)
- −$0.65
- −41.3% YoY · −62.5% QoQ
Source: XBRL data from the Stoke Therapeutics, Inc. (STOK) Q3 2025 10-Q on SEC EDGAR. USD.
Stoke Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New clinical trial risk: Phase 3 EMPEROR study for zorevunersen initiated May 2025 with first patient dosed August 2025, increasing development and regulatory risk
- Updated regulatory risk: June 2024 U.S. Supreme Court decision on Chevron doctrine may cause increased FDA challenges and regulatory delays
- Most impactful compliance risk: FDA partial clinical hold removed but future holds possible; dosing limits imposed on chronic toxicology studies in 2022
- Operational risk: Patient enrollment for rare diseases Dravet syndrome (1:15,600 incidence) and ADOA (1:30,000 incidence) may delay trials and revenue growth
- Financial risk: Continued operating losses anticipated with no revenue; need additional funding to advance product development and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stoke Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.